| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5310912 | GE HLTHCARE INC | Iodinated neuroprobe for mapping monoamine reuptake sites |
Feb, 2013
(11 years ago) | |
Datscan is owned by Ge Hlthcare Inc.
Datscan contains Ioflupane I-123.
Datscan has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Datscan are:
- US5310912
Datscan was authorised for market use on 14 January, 2011.
Datscan is available in solution;intravenous dosage forms.
Drug patent challenges can be filed against Datscan from 14 January, 2015.
The generics of Datscan are possible to be released after 14 January, 2016.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jan 14, 2016 |
Drugs and Companies using IOFLUPANE I-123 ingredient
NCE-1 date: 14 January, 2015
Market Authorisation Date: 14 January, 2011
Treatment: NA
Dosage: SOLUTION;INTRAVENOUS
More Information on Dosage
DATSCAN family patents
